46 results about "Helicobacter Infections" patented technology

The invention relates to the field of microorganisms, and discloses lactobacillus plantarum with an antibacterial effect and application of the lactobacillus plantarum, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.33151. The strain provided by the invention has relatively strong cholate resistance, gastric acid resistance, acid production and H2O2 production capabilities, and has a relatively strong bacteriostatic effect on common pathogenic bacteria such as staphylococcus aureus, candida albicans, escherichia coli, salmonella and helicobacter pylori; the compound can inhibit the activity of urease, interfere helicobacter pylori colonization and the like to inhibit helicobacter pylori infection or reduce the symptoms of helicobacter pylori infection and reduce the disease degree of mice with colitis, can be used for preparing microbial preparations, and has the potential of preparing drugs for preventing and / or treating diseases caused by helicobacter pylori infection.

The invention discloses a composition for treating insomnia. Comprising probiotic compounds: lactobacillus plantarum, bifidobacterium lactis, lactobacillus crispatus, lactobacillus acidophilus, lactobacillus rhamnosus, bifidobacterium bifidum, lactobacillus reuteri, lactobacillus casei, lactobacillus bulgaricus, lactobacillus fermentum, lactobacillus gasseri, lactococcus lactis, bifidobacterium longum, lactobacillus salivarius, bifidobacterium breve, streptococcus thermophilus and lactobacillus paracasei; lactobacillus helveticus; and traditional Chinese medicine components and prebiotics. Probiotics are matched with traditional Chinese medicines with homology of medicine and food, and corresponding prebiotics are supplemented, so that the balance of intestinal flora can be adjusted and information transmission between intestines and cranial nerves can be promoted through the synergistic effect of the probiotics and the corresponding prebiotics, and then gastrointestinal inflammation, ulcer, helicobacter pylori infection, constipation and insomnia are treated or improved; and treating or improving spleen and stomach disharmony, liver qi stagnation, excessive heart fire, fire excess from yin deficiency, heart-kidney disharmony caused by emotion, pressure, diseases and the like, and insomnia caused by the symptoms.

The invention discloses lactobacillus fermented concentrated asparagus extracted juice with the effect of preventing helicobacter pylori infection as well as preparation and application of the lactobacillus fermented concentrated asparagus extracted juice, and belongs to the technical field of food biotechnology and microbial fermentation. The concentrated asparagus beverage is prepared from the following raw materials: 20-50 parts of concentrated asparagus extract juice, 50-80 parts of purified water, 2-6 parts of glucose, 2-4 parts of white granulated sugar, 0.01-0.1 part of sodium D-isoascorbate and 0.001-0.01 part of compound lactic acid bacteria. The fermented and concentrated asparagus extraction juice is prepared by taking asparagus as a raw material, crushing, extracting, concentrating and fermenting, and the antioxidant capacity, the inhibition capacity on helicobacter pylori, the prevention and treatment effects on helicobacter pylori infection and the like of the obtained fermented and concentrated asparagus extraction juice are obviously improved. The asparagus extracted juice can be widely applied to the field of prevention and / or treatment of helicobacter pylori infection, and is particularly applied to preparation of drugs for prevention and / or treatment of helicobacter pylori infection.

The invention provides application of bifidobacterium breve in preparation of a product for resisting gastric ulcer and gastric inflammation caused by helicobacter pylori, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium breve NKU BB1-2 is GDMCC NO: 65956, and the bifidobacterium breve NKU BB1-2 can antagonize helicobacter pylori colonization and relieve gastric ulcer aggravation caused by helicobacter pylori. The bifidobacterium breve NKU BB 1-2 has good helicobacter pylori antagonism ability in an in-vitro environment, and can significantly inhibit colonization growth of helicobacter pylori; animal experiments show that the bifidobacterium breve NKU BB 1-2 can relieve gastric ulcer aggravation caused by helicobacter pylori infection in vivo, and the gastric mucosa lesion is relieved, the stomach inflammation is relieved, and the stomach pH value is increased; in addition, the bifidobacterium breve NKU BB1-2 can also significantly improve the diversity of stomach microorganisms, regulate and improve the structure of the stomach microorganisms, and assist antagonism and removal of helicobacter pylori infection.

The invention belongs to the technical field of application of natural products, and particularly relates to an anti-helicobacter pylori natural product composition and application, the anti-helicobacter pylori natural product composition comprises raspberry extract and cinnamon extract, and the composition contains anti-helicobacter pylori active substances. Besides, the natural product composition is combined with a clinical standard treatment method for treating helicobacter pylori, so that the curative effect can be further improved, and the gastrointestinal motility can be enhanced by adjusting intestinal flora disorder caused by pylorus infection, reducing toxic and side effects of antibiotic treatment, protecting gastric mucosa and enhancing gastrointestinal motility. The composition consists of two natural medicinal and edible plant extracts, is suitable for long-term use and has few adverse reactions. The Lycojaponicumin C can be used for preparing anti-helicobacter pylori medicines and preventive health-care foods, has obvious significance in prevention and treatment of helicobacter pylori infection, and has a good development prospect.

The invention relates to the use of herbal preparation, characterized by presence of 4 dominant compounds (carvacrol a from about 35% to about 50%, γ-terpinene from about 10% to about 30%, thymol from about 10% to about 25%, p-cymene from about 8% to about 20%, as expressed in % of total peak area in GC / MS chromatogram), obtained by mixing at least two essential oils from species selected from the group of genera Satureja L., Origanum L. and Thymus L., to prepare food supplement or medicament for treatment and prevention of gastric Helicobacter pylori infection in humans. The mixture may be placed on liquid or solid carrier and capsulated in non gastro-resistant capsules. The invention also relates to dosage regiment of herbal preparation for treatment and prevention of patients with Helicobacter pylori infection which leads to successful eradication of bacteria without any side-effects.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine compound preparation for treating helicobacter pylori infection and a preparation method thereof. The invention provides a traditional Chinese medicine compound preparation for treating helicobacter pylori infection. The traditional Chinese medicine compound preparation comprises the following components in parts by mass: 3-7 parts of coptis chinensis, 8-12 parts of scutellaria baicalensis, 13-17 parts of dandelion, 3-5 parts of fructus evodiae, 13-17 parts of fried coix seeds, 13-17 parts of codonopsis pilosula, 8-12 parts of rhizoma pinelliae preparata and 5-7 parts of liquorice. Research results show that the total effective rate of traditional Chinese medicine syndromes of a test group reaches 91.30% and is obviously higher than 69.57% of that of a control group. In addition, the Hp eradication rate of a test group also reaches 91.30%, which is obviously superior to the Hp eradication rate (69.57%) of a control group. Therefore, the traditional Chinese medicine compound has a synergistic enhancement effect in the aspects of improving clinical symptoms of patients and eradicating Hp, and is especially suitable for spleen and stomach damp-heat (or cold and heat intermingled) type patients after treatment failure of a standard quadruple therapy.

This invention relates to the field of pharmaceutical formulation technology, specifically to a sustained-release formulation of rifabutin, and more specifically, to a sustained-release rifabutin formulation composition for treating Helicobacter pylori infection. The key technical point of this invention is that it uses a novel antibiotic for treating Helicobacter pylori infection as the active ingredient, supplemented with specific inactive ingredients, including a hydrophilic gel-type matrix sustained-release material, a swelling agent, a buoyancy aid, and a lubricant. Through the synergistic effect of the hydrophilic gel-type matrix sustained-release material, the swelling agent, and the buoyancy aid, the composition can rapidly swell in gastric juice and maintain a floating state, thereby significantly prolonging the residence time of the formulation in the stomach and upper small intestine. This invention solves the technical problem of conventional formulations having a short residence time in the stomach and requiring frequent administration to maintain an effective antibacterial concentration, achieving the goal of effectively eradicating Helicobacter pylori by reducing the number of doses while maintaining an effective concentration at the site of infection for a longer period.

This invention provides the application of *Bifidobacterium breve* in the preparation of products for treating gastric ulcers and gastric inflammation caused by *Helicobacter pylori*, belonging to the field of microbial technology. The *Bifidobacterium breve* NKU BB1-2 of this invention, with accession number GDMCC NO: 65956, can antagonize *Helicobacter pylori* colonization and alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori*. In vitro, *Bifidobacterium breve* NKU BB1-2 exhibits good antagonistic ability against *Helicobacter pylori*, significantly inhibiting its colonization and growth. Animal experiments show that *Bifidobacterium breve* NKU BB1-2 can alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori* infection in vivo, manifested as reduced gastric mucosal damage, reduced gastric inflammation, and increased gastric pH. Furthermore, *Bifidobacterium breve* NKU BB1-2 can significantly enhance gastric microbial diversity, regulate and improve the gastric microbial structure, and assist in antagonizing and eradicating *Helicobacter pylori* infection.

This invention provides a composition, preparation method, and application for preventing Helicobacter pylori infection. The composition comprises a mixture of outer membrane vesicles and a solution of *Ackermania pseudomallei* bacteria; the outer membrane vesicle mixture is composed of outer membrane vesicles of *Salmonella* mutant strain QS0074 and outer membrane vesicles of *Escherichia coli* Nissle 1917 at a weight ratio of 2:1; the weight-to-volume ratio of the outer membrane vesicle mixture to the *Ackermania pseudomallei* bacterial solution is 1 mg:1 mL. The composition obtained by this invention significantly outperformed the control group in challenge tests, demonstrating a highly effective preventive effect against Helicobacter pylori infection. Furthermore, the components of the composition of this invention exhibit significant synergistic effects in inducing secretory IgA levels in mice and inducing resistance to Helicobacter pylori infection, showing promising application prospects.

The application provides a use of a nitrothiazole derivative in preparation of an antibacterial agent for inhibiting helicobacter pylori, and belongs to the field of pharmacy.The structure of the amino nitrothiazole derivative is shown as formula I.The experimental results show that the compound can effectively inhibit the growth of helicobacter pylori, and the inhibiting effect is better than that of control compounds nitazoxanide and lauric acid; the compound can effectively treat mice infected with helicobacter pylori, clear helicobacter pylori in the stomach and reduce the inflammatory response of the stomach tissue, and the treatment effect is better than that of control compounds nitazoxanide and lauric acid.The compound provided by the application can be used for preparing the antibacterial agent for inhibiting helicobacter pylori, and can be used for preparing a medicine for preventing and / or treating helicobacter pylori infection and related diseases caused by the helicobacter pylori, and has a wide application prospect.

The disclosure discloses a strain of Lactobacillus crispatus capable of preventing and / or treating Helicobacter pylori infection, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus crispatus CCFM1118. The Lactobacillus crispatus CCFM1118 can inhibit Helicobacter pylori, specifically embodied in that: (1) the diameter of an inhibition zone of supernatant of the Lactobacillus crispatus CCFM1118 on Helicobacter pylori can reach 13.14 mm; and (2) the Lactobacillus crispatus CCFM1118 can significantly reduce the adhesion of Helicobacter pylori to AGS cells. Therefore, the Lactobacillus crispatus CCFM1118 has great application prospects in inhibiting Helicobacter pylori (not for the purposes of disease diagnosis and treatment) and preparing Helicobacter pylori inhibitors.

The invention discloses freeze-dried powder and capsules for treating intractable helicobacter pylori infection as well as a preparation method and application of the freeze-dried powder and capsules, and belongs to the technical field of biological medicines. The invention provides a preparation method of freeze-dried powder for treating intractable helicobacter pylori infection, which comprises the following steps: acquiring gastric mucous layer flushing fluid which contains gastric microorganisms; filling the obtained gastric mucous layer flushing fluid into an eggplant-shaped bottle, connecting a low-temperature rotator, and rotating for a certain time under a low-temperature condition until the bacterial liquid adheres to the wall; and after the bacterial liquid adheres to the wall, taking down the eggplant-shaped bottle, mounting the eggplant-shaped bottle on a freeze-drying machine, and freeze-drying at low temperature for a certain time to prepare freeze-dried powder. The capsule prepared from the freeze-dried powder prepared by using the preparation method disclosed by the invention can overcome gastrointestinal flora disorder caused by conventional anti-helicobacter pylori infection treatment, repair unbalanced gastric microbiota of an infected patient, and avoid complex operations or invasive operations possibly involved in traditional flora transplantation, such as gastroscopy or nasogastric tubes and the like.

In particular, the present invention relates to a composition consisting of 2 '-fucosyllactose and 3-fucosyllactose. The composition of the present invention is based on fucosyllactose, is used for preventing and / or treating helicobacter pylori infection, and is a safe, effective and less susceptible to drug resistance.

The invention belongs to the technical field of biological medicine, discloses nanocapsule-loaded in-situ gel for treating H. pylori infection and reversing intestinal metaplasia of gastric tissue and application of the nanocapsule-loaded in-situ gel, and particularly discloses nanocapsule-loaded in-situ gel which comprises a nanocapsule and pH-responsive gel, the nanocapsule is dispersed in the gel, and the pH-responsive gel is a pH-responsive gel. Comprising an active drug, a macromolecular substance for coating the active drug and a structure stabilizer. According to the nanocapsule-loaded in-situ gel provided by the invention, the nanocapsule-loaded in-situ gel is directionally released on one side by responding to the change of the pH value of an H.pylori infected part, and the nanocapsule responds to lipase secreted by H.pylori to accurately release an active drug, so that efficient sterilization is realized, and damage caused by infection is relieved. Meanwhile, the gel can also effectively reverse gastrointestinal metaplasia caused by H.pylori infection, further reduces the risk of gastric cancer, and provides a new thought for gastric cancer prevention.

The present invention relates to an inhibitor of the Helicobacter pylori (H. pylori) cell purine nucleotide salvage pathway (reserve pathway) for use in the treatment of H. pylori infection and / or the treatment or prevention of a disease associated with this infection, such as gastritis and duodenitis, gastric and duodenal ulcers, as well as gastric cancer and MALT-type lymphoma, as well as pancreatic cancer or neurodegenerative diseases or disorders. The present invention also provides a pharmaceutical composition comprising such an inhibitor of the H. pylori cell purine nucleotide salvage pathway and at least one pharmaceutically acceptable excipient. The present invention further provides a pharmaceutical composition comprising such an inhibitor of the H. pylori cell purine nucleotide salvage pathway, at least one pharmaceutically acceptable excipient and at least one additional drug for the treatment of H. pylori infection, selected in particular from an antibiotic, a proton pump inhibitor and a bismuth salt.

The present invention pertains to a Lonicera japonica flower water extract composition for preventing or treating Helicobacter pylori infection, the composition containing secoxyloganin as an active ingredient. The extract contains a specific amount of secoxyloganin, and thus exhibited excellent antibacterial effects when used on Helicobacter pylori bacteria, and exhibited excellent effects in terms of reducing Helicobacter pylori IgG antibody expression in the blood, alleviating histopathological lesions, and reducing cytokine expression when used on Helicobacter pylori-infected mice. Thus, the Lonicera japonica flower water extract of the present invention can be usefully used as a composition for preventing or treating Helicobacter pylori infection.

The invention discloses an anti-helicobacter pylori combined medicine, and aims to provide the anti-helicobacter pylori combined medicine which has a remarkable inhibition effect on a helicobacter pylori standard strain SS1, can effectively destroy the biological membrane structure of the helicobacter pylori standard strain SS1 and has a synergistic antibacterial effect. According to the technical scheme, the traditional Chinese medicine composition consists of fructus amomi essential oil extract and clinically common antibiotics for treating helicobacter pylori infection, experiments show that the technology provided by the invention has a synergistic effect with metronidazole, levofloxacin, clarithromycin and amoxicillin; the effect of reducing the dosage of antibiotics in clinical application is achieved, and the potential application value is achieved for improving the current drug resistance situation of the antibiotics; belongs to the technical field of medicine.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

The application discloses a combined medicine against helicobacter pylori, and aims to provide a combined medicine against helicobacter pylori, which has a significant inhibiting effect on a standard strain SS1 of helicobacter pylori, can effectively destroy a biofilm structure of the standard strain SS1 of helicobacter pylori, and has a synergistic bacteriostatic effect. The technical scheme is that an extract of fructus amomi essential oil is combined with antibiotics commonly used in clinical treatment of helicobacter pylori infection. Experiments show that the technology provided by the application has a synergistic effect with metronidazole, levofloxacin, clarithromycin and amoxicillin. The technology has an effect of reducing the dosage of the antibiotics used in clinical application, has potential application value for improving the drug resistance status of the antibiotics, and belongs to the technical field of medicines.

The present application relates to the field of microorganisms, and discloses a lactobacillus plantarum with antibacterial efficacy and application thereof, wherein the lactobacillus plantarum has a preservation number of CGMCC No.33151.The strain provided by the present application has strong abilities of resisting bile salt, resisting gastric acid, producing acid and producing H2O2, and has strong bacteriostatic effects on common pathogenic bacteria such as staphylococcus aureus, candida albicans, escherichia coli, salmonella and helicobacter pylori, and can inhibit the activity of urease, interfere with the colonization of helicobacter pylori and the like, so as to inhibit helicobacter pylori infection, reduce the symptoms of helicobacter pylori infection and reduce the disease degree of colonitis mice, and can be used for preparing a microbial preparation and has potential for preparing a medicine for preventing and / or treating diseases caused by helicobacter pylori infection.

The invention discloses a traditional Chinese medicine composition for treating refractory helicobacter pylori infection and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 15-20 parts of codonopsis pilosula, 10-15 parts of roasted rhizoma atractylodis macrocephalae, 15-20 parts of oldenlandia diffusa, 6-9 parts of coptis chinensis, 6-9 parts of rhizoma pinellinae praeparata, 6-9 parts of curcuma zedoary and 6-9 parts of raw liquorice. The invention also provides a preparation method and a traditional Chinese medicine preparation of the traditional Chinese medicine composition. The traditional Chinese medicine composition and the traditional Chinese medicine preparation thereof are simple in prescription, can be used for effectively treating intractable helicobacter pylori infection, and are beneficial to relieving the medicine taking and economic burden of patients, improving the compliance and reducing the occurrence of adverse reactions.

The invention discloses a composite probiotic agent and application thereof in treatment of helicobacter pylori infection. The compound probiotic agent is prepared from lactobacillus gasseri, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. The compound probiotic agent disclosed by the invention has a high inhibition rate on helicobacter pylori, and can effectively improve gastric tissue damage and systemic inflammatory response caused by helicobacter pylori infection.

New probiotic clones have emerged that have enhanced activity against Helicobacter pylori infection. The new clones are derived from selected strains of Lactobacillus acidophilus and Bifidobacterium animalis lactis sp. They are advantageously insensitive to antibiotics currently used to treat Helicobacter pylori infection, which makes them ideal for co-therapy with said antibiotics in the eradication of Helicobacter pylori infection. Synergistic effects of combinations between the present probiotics and their strong adjuvant effect on the action of antibiotics on Helicobacter pylori are reported herein.

The present invention discloses a driven oral nanoformulation for intracellular Helicobacter pylori, wherein the nanoformulation includes a nanocarrier and a loaded drug, and the surface of the nanoformulation is modified with a bacteria-targeting functional polymer A-PEG-B and a mucus layer penetrating functional inclusion compound X@CD-TPGS. The driven oral nanoformulation for intracellular Helicobacter pylori of the present invention can maintain good stability in a gastric acid environment, and can give the nanoformulation gastric mucus layer penetration performance through the catalytic gas production approach, and then reach the Helicobacter pylori infection site through the bacteria-targeting function of the nanoformulation, and activate host cell autophagy under the synergistic action of the nanoformulation and the loaded drug, thereby achieving the effect of enhancing the clearance of intracellular infected Helicobacter pylori. The present invention provides a new approach for the efficient delivery of chemical drugs for treating Helicobacter pylori infection and the treatment of intracellular Helicobacter pylori infection.

The invention provides sea cucumber polysaccharide capable of preventing and treating helicobacter pylori infection and a preparation method and application thereof, and belongs to the technical field of marine organism polysaccharide preparation. The sea cucumber polysaccharide comprises the following components: 35-44% of total sugar, 19-25% of sulfate group, 4.5-5.0% of protein, 3.0-3.5% of uronic acid, 4.0-4.7% of amino sugar, 7.0-9.0% of water and 20-25% of ash content, has the molecular weight of 16-1916 kDa, mainly contains fucose, mannose and galactose, and also contains a small amount of glucosamine, galactosamine, glucuronic acid and glucose. The sea cucumber polysaccharide has good anti-helicobacter pylori activity in vitro, and the minimum effective dose is 20 mg / mL; in vivo, the sea cucumber polysaccharide can reduce stomach inflammation response and helicobacter pylori colonization amount in the helicobacter pylori infection process, reduce the infection rate, and also can reduce the stomach inflammation level and the helicobacter pylori colonization amount after infection, that is, the obtained sea cucumber polysaccharide has prevention and treatment effects on helicobacter pylori infection. When the sea cucumber polysaccharide with good helicobacter pylori inhibitory activity is applied to the fields of food nutrition and pharmacy, the industrial additional value of sea cucumbers can be greatly improved.

The invention belongs to the technical field of biology, and particularly discloses a PCR (Polymerase Chain Reaction) kit for synchronously detecting helicobacter pylori infection and drug resistance genes. The kit comprises a primer probe group for detecting a clarithromycin resistance site A2142G / A2143G of a helicobacter pylori 23SrRNA gene, a primer probe group for detecting a levofloxacin resistance site 260T / 261A / 261G / 271A / 271T / 272G of a gyrA gene, a primer probe for confirming an infected 16S rRNA gene and a primer probe for monitoring a human GAPDH reference gene of the effectiveness of a sample. Through single-tube four-channel fluorescence detection, the infection state and eight drug-resistant sites can be synchronously interpreted. A multi-probe combination is designed for a gyrA high-frequency synonymous mutation region, so that the false negative risk is remarkably reduced. The sensitivity of the kit reaches 10 copies / microliter, detection is completed within 3 hours, high specificity and clinical practicability are achieved, and drug resistance spectrum support is provided for individualized precise medication of helicobacter pylori.

The application discloses application of Wangshi Baochi pills in treatment of Helicobacter pylori infection and belongs to the technical field of medicines. The application provides the application of the Wangshi Baochi pills in treatment of Helicobacter pylori infection, which can achieve ideal treatment effects under the condition that the dosage of antibiotics is halved and bismuth agents are not used, and can better relieve the clinical symptoms of pain, belching, acid regurgitation and heartburn.

The present disclosure provides methods for effectively preserving test samples utilized in detecting Helicobacter pylori. The present disclosure also provides methods for accurately detecting antibiotic-resistant genotypes of Helicobacter pylori, as well as methods for treating Helicobacter pylori infected-diseases. The disclosed methods effectively improve the efficiency and practicality of both detecting and treating antibiotic-resistant Helicobacter pylori.

The invention provides a self-propelled drug delivery carrier for helicobacter pylori diagnosis and gastric mucosa protection and a preparation method thereof. The drug delivery carrier is composed of bismuth oxide particles, a bacterial targeting functional coating B-CS and a gastric acid driven propelling functional coating X. The drug delivery carrier keeps good stability in a gastric acid environment, the carrier is endowed with gastric mucous layer penetrating performance by directionally generating gas in the acid environment, and the carrier can accurately reach a helicobacter pylori infected part through the bacterial targeting functional coating B-CS. Bismuth oxide particles serve as a developing agent, accurate positioning of an infected part is achieved, bismuth ions are released in a gastric acid environment, and the bismuth oxide particles and chitosan jointly play a role in protecting gastric mucosa. The drug delivery carrier has a self-propelling capability and a targeting function, improves the delivery efficiency and local concentration of the drug, and is suitable for diagnosis of helicobacter pylori infection and prevention and treatment of stomach diseases.